Epigenetic upregulation of Schlafen11 renders WNT- and SHH-activated medulloblastomas sensitive to cisplatin
Authors:
- 23 October 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (5) , 899-912
Abstract
Intensive chemotherapeutic regimens with craniospinal irradiation have greatly improved survival in medulloblastoma patients. However, survival markedly differs among molecular subgroups and their biomarkers are unknown. Through unbiased screening, we found Schlafen family member 11 (SLFN11), which is known to improve response to DNA damaging agents in various cancers, to be one of the top prognostic markers in medulloblastomas. Hence, we explored the expression and functions of SLFN11 in medulloblastoma. SLFN11 expression for each subgroup was assessed by immunohistochemistry in 98 medulloblastoma patient samples and by analyzing transcriptomic databases. We genetically or epigenetically modulated SLFN11 expression in medulloblastoma cell lines and determined cytotoxic response to the DNA damaging agents cisplatin and topoisomerase I inhibitor SN-38 in vitro and in vivo. High SLFN11 expressing cases exhibited significantly longer survival than low expressing cases. SLFN11 was highly expressed in the WNT-activated subgroup and in a proportion of the SHH-activated subgroup. While WNT activation was not a direct cause of the high expression of SLFN11, a specific hypomethylation locus on the SLFN11 promoter was significantly correlated with high SLFN11 expression. Overexpression or deletion of SLFN11 made medulloblastoma cells sensitive and resistant to cisplatin and SN-38, respectively. Pharmacological upregulation of SLFN11 by the brain-penetrant histone deacetylase-inhibitor RG2833 markedly increased sensitivity to cisplatin and SN-38 in SLFN11-negative medulloblastoma cells. Intracranial xenograft studies also showed marked sensitivity to cisplatin by SLFN11-overexpression in medulloblastoma cells. High SLFN11 expression is one factor which renders favorable outcomes in WNT-activated and a subset of SHH-activated medulloblastoma possibly through enhancing response to cisplatin.Keywords
Funding Information
- Japanese Society for Promotion of Science (17K16632, 19K09476, 21KK0156, 22K16679, 17K17739, 20K17955, 19K18418, JP19H03505)
- NIH Grant (R01CA255331)
- National Cancer Institute (Z01-BC-006150)
This publication has 47 references indexed in Scilit:
- The Wnt/β-Catenin Pathway Cross-Talks with STAT3 Signaling to Regulate Survival of Retinal Pigment Epithelium CellsPLOS ONE, 2012
- Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agentsProceedings of the National Academy of Sciences, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomasActa Neuropathologica, 2012
- Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samplesActa Neuropathologica, 2011
- Canonical Wnt signaling is involved in switching from cell proliferation to myogenic differentiation of mouse myoblast cellsJournal of Molecular Signaling, 2011
- More forks on the road to replication stress recoveryJournal of Molecular Cell Biology, 2011
- Subtypes of medulloblastoma have distinct developmental originsNature, 2010
- Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological FeaturesPLOS ONE, 2008
- c-Myc Overexpression Causes Anaplasia in MedulloblastomaCancer Research, 2006